Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. boosted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 7.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,021,230 shares of the company’s stock after acquiring an additional 843,996 shares during the period. Vanguard Group Inc. owned about 0.08% of Denali Therapeutics worth $244,993,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of DNLI. Fox Run Management L.L.C. purchased a new position in shares of Denali Therapeutics in the 4th quarter valued at about $788,000. KLP Kapitalforvaltning AS acquired a new position in Denali Therapeutics in the fourth quarter valued at approximately $532,000. American Century Companies Inc. increased its stake in Denali Therapeutics by 6.5% in the fourth quarter. American Century Companies Inc. now owns 480,529 shares of the company’s stock valued at $9,793,000 after purchasing an additional 29,155 shares during the last quarter. Yiheng Capital Management L.P. raised its holdings in Denali Therapeutics by 16.7% during the fourth quarter. Yiheng Capital Management L.P. now owns 700,098 shares of the company’s stock worth $14,268,000 after purchasing an additional 100,000 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its position in shares of Denali Therapeutics by 18.6% during the 4th quarter. Teacher Retirement System of Texas now owns 38,178 shares of the company’s stock worth $778,000 after buying an additional 5,987 shares during the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Trading Down 7.9 %

Shares of DNLI opened at $11.78 on Friday. Denali Therapeutics Inc. has a 12-month low of $11.33 and a 12-month high of $33.33. The stock has a market cap of $1.71 billion, a P/E ratio of -4.27 and a beta of 1.58. The company has a 50-day moving average of $18.06 and a two-hundred day moving average of $22.66.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.08. As a group, analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Steve E. Krognes sold 3,339 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total transaction of $69,484.59. Following the sale, the director now owns 25,757 shares in the company, valued at $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Carole Ho sold 12,255 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the completion of the transaction, the insider now owns 178,580 shares of the company’s stock, valued at $3,610,887.60. The trade was a 6.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 44,860 shares of company stock valued at $909,039 in the last ninety days. Insiders own 7.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DNLI. Robert W. Baird began coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 target price on the stock. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research report on Monday, December 16th. Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They set a “buy” rating and a $31.00 price target on the stock. Oppenheimer reduced their price objective on Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Finally, Bank of America lowered their price objective on shares of Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $37.20.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.